Status:
COMPLETED
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Leukemia, Myeloid, Chronic
Leukemia, Lymphocytic, Acute, L2
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leuke...
Eligibility Criteria
Inclusion
- Diagnosis of accelerated phase or blast phase CML or Ph+ ALL
- Intolerant or resistant to imatinib mesylate
- 18 years of age or older
- ECOG performance 0-2 (greater than 50% of time out of bed)
- Adequate liver and kidney function
Exclusion
- Pregnant or breastfeeding females
- History of significant cardiac disease
- History of significant bleeding disorder (not CML)
- Prisoners
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2007
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00298987
Start Date
February 1 2006
End Date
June 1 2007
Last Update
February 8 2010
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Corona, California, United States
2
Local Institution
Aurora, Colorado, United States
3
Local Institution
Colorado Springs, Colorado, United States
4
Local Institution
Waterford, Connecticut, United States